Successful treatment of KIT D816V-positive, imatinib-resistant systemic mastocytosis with interferon-alpha

Internal Medicine

Volumn 48, Issue 22, 2009, Pages 1973-1978

  Yoshida, Chikamasa ^a   Takeuchi, Makoto ^a   Tsuchiyama, Junjiro ^b   Sadahira, Yoshito ^b  

^a Department of Internal Medicine   (Japan)

^b KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

Imatinib; Interferon alpha; KIT; Mastocytosis; Myeloproliferative neoplasm

Indexed keywords

ALKALINE PHOSPHATASE; ALPHA INTERFERON; ASPARTIC ACID; BCR ABL PROTEIN; FLIP 1 LIKE 1 PROTEIN PLATELET DERIVED GROWTH FACTOR A FUSION PROTEIN; HYBRID PROTEIN; IMATINIB; LACTATE DEHYDROGENASE; PREDNISOLONE; QUETIAPINE; STEM CELL FACTOR RECEPTOR; TRYPTASE; UNCLASSIFIED DRUG; VALINE;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; AMINO ACID SUBSTITUTION; ARTICLE; BONE MARROW BIOPSY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; DISEASE COURSE; DNA SEQUENCE; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENTIATION; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EOSINOPHILIA; ERYTHROCYTE TRANSFUSION; FEMALE; FEVER; GENETIC ANALYSIS; HEPATOMEGALY; HEPATOSPLENOMEGALY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LABORATORY DIAGNOSIS; LACTATE DEHYDROGENASE BLOOD LEVEL; LOW DRUG DOSE; MAST CELL; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; ONCOGENE C KIT; PALLOR; POINT MUTATION; SCHIZOPHRENIA; SPLENOMEGALY; SYSTEMIC MASTOCYTOSIS; THROMBOCYTE COUNT;

BONE MARROW; DRUG RESISTANCE; FEMALE; HUMANS; INTERFERON-ALPHA; MAST CELLS; MASTOCYTOSIS, SYSTEMIC; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PIPERAZINES; POINT MUTATION; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES;

EID: 71049186065     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.48.2294     Document Type: Article

References (19)

1. Valent P, Akin C, Sperr WR, et al. Mastocytosis: pathology, genetics, and current options for therapy. Leuk Lymphoma 46: 35-48, 2005.
2. Metcalfe DD. Mast cells and mastocytosis. Blood 112: 946-956, 2008.
3. Horny HP, Sotlar K, Sperr WR, Valent P. Systemic mastocytosis with associated clonal haematological non-mast cell lineage diseases: a histopathological challenge. J Clin Pathol 57: 604-608, 2004. (Pubitemid 38725760)
4. Robyn J, Metcalfe DD. Systemic mastocytosis. Adv Immunol 89: 169-243, 2006.
5. Pardanani A, Brockman SR, Paternoster SF, et al. FIP1 L1- PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood 104: 3038-3045, 2004. (Pubitemid 39507117)
6. Walz C, Metzgeroth G, Haferlach C, et al. Characterization of three new imatinib-responsive fusion genes in chronic myeloproliferative disorders generated by disruption of the platelet-derived growth factor receptor beta gene. Haematologica 92: 163-169, 2007. (Pubitemid 46852416)
7. Yavuz AS, Lipsky PE, Yavuz S, Metcalfe DD, Akin C. Evidence for the involvement of a hematopoietic progenitor cell in systemic mastocytosis from single-cell analysis of mutations in the c-kit gene. Blood 100: 661-665, 2002. (Pubitemid 34761133)
8. Pardanani A, Reeder T, Li CY, Tefferi A. Eosinophils are derived from the neoplastic clone in patients with systemic mastocytosis and eosinophilia. Leuk Res 27: 883-885, 2003. (Pubitemid 36809082)
9. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 22: 14-22, 2008.
10. Akin C, Brockow K, D'Ambrosio C, et al. Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. Exp Hematol 31: 686-692, 2003. (Pubitemid 36945381)
11. Peng B, Lloyd P, Schran H. Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 44: 879-894, 2005.
12. DeVane CL, Nemeroff CB. Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. Clin Pharmacokinet 40: 509-522, 2001. (Pubitemid 32738658)
13. Deininger MW, O'Brien SG, Ford JM, Druker BJ. Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol 21: 1637-1647, 2003. (Pubitemid 46594119)
14. Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 96: 925-932, 2000.
15. Horny HP, Metcalfe DD, Bennett JM, et al. Mastocytosis. In: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Swerdlow SH, Campo E, Harris NL, et al, Eds. IARC, Lyon, 2008: 54-63.
16. Pullarkat VA, Bueso-Ramos C, Lai R, et al. Systemic mastocytosis with associated clonal hematological non-mast-cell lineage disease: analysis of clinicopathologic features and activating c-kit mutations. Am J Hematol 73: 12-17, 2003. (Pubitemid 36504572)
17. Valent P, Akin C, Sperr WR, et al. Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria. Leuk Res 27: 635-641, 2003. (Pubitemid 36398099)
18. Shah NP, Lee FY, Luo R, Jiang Y, Donker M, Akin C. Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood 108: 286-291, 2006. (Pubitemid 43990640)
19. Przepiorka D, Giralt S, Khouri I, Champlin R, Bueso-Ramos C. Allogeneic marrow transplantation for myeloproliferative disorders other than chronic myelogenous leukemia: review of forty cases. Am J Hematol 57: 24-28, 1998. (Pubitemid 28047194)